PsychoGenics and Amylin Pharmaceuticals have formed Psylin Neurosciences, a new company that will focus on the discovery and development of peptide hormones for treatment of psychiatric disorders. PsychoGenics and Amylin participated equally in a Series A financing of Psylin to fund the company for approximately the next two years.
"Given the richness of the unique PHORMOL library, we expect several drug candidates to emerge from this collaboration and the creation of Psylin affords both companies the opportunity to pursue a new area of research while maintaining their corporate focus," says Emer Leahy, PhD, president and CEO of PsychoGenics.
- see the release on the new company